ArticleBiomedicines2021
Identification of Sclerostin as a Putative New Myokine Involved in the Muscle-to-Bone Crosstalk.
Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Impaired Bone Physiology in Rheumatoid Arthritis: Can the Wnt Pathway be the Connecting Link Between the Synovium and the Bone?Mediterranean journal of rheumatology · 2026Review
- Irisin in Cartilage Homeostasis: Molecular Mechanisms and Therapeutic Implications for Osteoarthritis.Journal of functional morphology and kinesiology · 2026Review
- Irisin treatment counteracts bone loss and muscle atrophy in aged mice by reducing sclerostin expression in bone and skeletal muscle.Journal of translational medicine · 2026Article
- Peptide Receptor-Functionalized AuNP-Embedded Zwitterionic Biopolymeric Nanohydrogel for Electrochemical Sclerostin Sensing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bone tissue regeneration: role of osteocyte mechanosensing and mechanotransduction.Stem cells translational medicine · 2026Review
- Exploring osteosarcopenia from the gut microbiota perspective: mechanistic insights and therapeutic potentials based on the gut-muscle-bone Axis.Frontiers in microbiology · 2026Review
- Role of Branched-Chain Amino Acids in Mitigating Osteosarcopenia: An Experimental Study Using Ovariectomised Mice Models.Journal of cachexia, sarcopenia and muscle · 2025Article
- Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?International journal of molecular sciences · 2025Review
- Bone and muscle crosstalk in ageing and disease.Nature reviews. Endocrinology · 2025Review
- Bone-derived factors mediate crosstalk between skeletal and extra-skeletal organs.Bone research · 2025Review
- Repair mechanisms of bone system tissues based on comprehensive perspective of multi-omics.Cell biology and toxicology · 2025Review
- Elevated Circulating Sclerostin Levels in Frail Older Adults: Implications beyond Bone Health.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- The role of bone-derived factors in bone and muscle communication.Frontiers in endocrinology · 2025Review
- Osteokines in Nonalcoholic Fatty Liver Disease.Current obesity reports · 2024Review
- Glycogen Storage Disease Type I and Bone: Clinical and Cellular Characterization.Calcified tissue international · 2024Article
- Myoblast-Derived Galectin 3 Impairs the Early Phases of Osteogenesis Affecting Notch and Akt Activity.Biomolecules · 2024Article
- Article
- Wnt/β-catenin signaling pathway as an important mediator in muscle and bone crosstalk: A systematic review.Journal of orthopaedic translation · 2024Review
- Comparative Analysis of Myokines and Bone Metabolism Markers in Prepubertal Vegetarian and Omnivorous Children.Nutrients · 2024Article
- CRISPR interference provides increased cell type-specificity compared to the Cre-loxP system.iScience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Bone and muscle have been recognized as endocrine organs since they produce and secrete "hormone-like factors" that can mutually influence each other and other tissues, giving rise to a "bone-muscle crosstalk". In our study, we made use of myogenic (C2C12 cells) and osteogenic (2T3 cells) cell lines to investigate the effects of muscle cell-produced factors on the maturation process of osteoblasts. We found that the myogenic medium has inhibitory effects on bone cell differentiation and we identified sclerostin as one of the myokines produced by muscle cells. Sclerostin is a secreted glycoprotein reportedly expressed by bone/cartilage cells and is considered a negative regulator of bone growth due to its role as an antagonist of the Wnt/β-catenin pathway. Given the inhibitory role of sclerostin in bone, we analyzed its expression by muscle cells and how it affects bone formation and homeostasis. Firstly, we characterized and quantified sclerostin synthesis by a myoblast cell line (C2C12) and by murine primary muscle cells by Western blotting, real-time PCR, immunofluorescence, and ELISA assay. Next, we investigated in vivo production of sclerostin in distinct muscle groups with different metabolic and mechanical loading characteristics. This analysis was done in mice of different ages (6 weeks, 5 and 18 months after birth) and revealed that sclerostin expression is dynamically modulated in a muscle-specific way during the lifespan. Finally, we transiently expressed sclerostin in the hind limb muscles of young mice (2 weeks of age) via in vivo electro-transfer of a plasmid containing the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.